HIV, HCV and SARS-CoV-2: friends or foes? A case report

Submitted: 30 July 2020
Accepted: 9 February 2021
Published: 24 September 2021
Abstract Views: 831
PDF: 404
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Data about co-infection of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), HIV, and hepatitis C virus (HCV) are still scarce. We describe a patient hospitalized for sore throat, fatigue, and myalgia with a personal history of HIV and occult HBV infection. His antiretroviral therapy included bictegravir/emtricitabine/tenofovir alafenamide. The nasopharyngeal swab was positive for SARS-CoV-2 and laboratory testing showed acute HCV. Antiretroviral therapy was continued, but no specific therapy for SARS-CoV-2 was started. After 4 weeks, the nasopharyngeal swab resulted negative for SARS-CoV-2 and biochemical tests revealed undetectable HCV RNA with normalization of transaminases. To the best of our knowledge, this is the first reported case of acute HCV in a patient with HIV and SARS-CoV-2 co-infection.



PlumX Metrics


Download data is not yet available.


Zhao J, Liao X, Wang H, et al. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV. Clin Infect Dis 2020 [Epub ahead of print].
The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Coronavirus COVID-19 global cases. Available from: Accessed: July 28, 2020.
Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020;80:656-65. DOI:
Blanco JL, Ambrosini J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series, Lancet HIV 2020;7:e314-6. DOI:
Riva A, Conti F, Bernacchia D, et al. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res 2020;157:104826. DOI:
HÓ“rter G, Spinner CD, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection 2020 [Epub ahead of print]. DOI:
Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV.2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci 2020;25:117592. DOI:
Vizcarra P, Perez-Elias MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV 2020 [Epub ahead of print]. DOI:
Sanduzzi A, Sanduzzi Zamparelli S. Nasopharyngeal and oropharyngeal swabs, and/or serology for SARS COVID-19: what we are looking for? Int J Environ Res Public Health 2020;17:3289. DOI:
Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020 [Epub ahead of print]. DOI:
American Association for the Study of Liver Diseases. Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic. Released: April 7, 2020. Available from:
Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103:1283-97. DOI:
Izzi A, Messina A, Rinaldi L, et al. Editorial-Sofosbuvir/velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents. Eur Rev Med Pharmacol Sci 2020;24:5193-4.
Xiao C, Li X, Liu S, et al. HIV-1 did not contribute to the 2019-nCoV genome. Emerg Microb Infect 2020;9:379-81. DOI:

How to Cite

Garlatti Costa, E. ., Mazzaro, C., Grembiale, A., Berto, A., De Rosa, R. ., Grazioli, S., & Tonizzo, M. (2021). HIV, HCV and SARS-CoV-2: friends or foes? A case report. Italian Journal of Medicine, 15(3).